Nuvilex Inc. (NASDAQ:PMCB) Sees Significant Drop in Short Interest

Nuvilex Inc. (NASDAQ:PMCB) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totaling 79,793 shares, a decrease of 61.7% from the August 15th total of 208,161 shares. Based on an average daily trading volume, of 91,412 shares, the short-interest ratio is currently 0.9 days. Approximately 0.8% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded Nuvilex from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 2nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Nuvilex has an average rating of “Sell”.

Nuvilex Trading Up 1.8%

Shares of PMCB stock traded up $0.01 during trading hours on Friday, hitting $0.45. 48,490 shares of the company were exchanged, compared to its average volume of 92,904. Nuvilex has a 52 week low of $0.43 and a 52 week high of $1.51. The business has a 50 day moving average of $0.57 and a two-hundred day moving average of $0.68. The company has a market capitalization of $4.84 million, a PE ratio of -0.15 and a beta of 0.66.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.